Adding Docetaxel to ADT for High-Risk Nonmetastatic Prostate Cancer: Does It Help?

Leggi l'articolo originale


Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer.

Lascia un commento